BIA
BMRN icon

Bell Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bell Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.26K Sell
57
-102
-64% -$5.59K ﹤0.01% 1156
2026
Q1 		$8.98K Buy
159
+102
+179% +$5.95K ﹤0.01% 718
2025
Q4 		$3.39K Buy
57
+15
+36% +$817 ﹤0.01% 1145
2025
Q3 		$2.27K Buy
42
+35
+500% +$2K ﹤0.01% 1291
2025
Q2 		$385 Sell
7
-31
-82% -$1.82K ﹤0.01% 1811
2025
Q1 		$2.69K Buy
38
+15
+65% +$1.01K ﹤0.01% 1188
2024
Q4 		$1.51K Buy
23
+10
+77% +$670 ﹤0.01% 1434
2024
Q3 		$914 Sell
13
-19
-59% -$1.59K ﹤0.01% 1621
2024
Q2 		$2.63K Buy
32
+5
+19% +$416 ﹤0.01% 1243
2024
Q1 		$2.36K Buy
27
+6
+29% +$537 ﹤0.01% 1282
2023
Q4 		$2.02K Sell
21
-16
-43% -$1.42K ﹤0.01% 1318
2023
Q3 		$3.27K Buy
37
+16
+76% +$1.42K ﹤0.01% 1030
2023
Q2 		$1.82K Buy
21
+6
+40% +$565 ﹤0.01% 1346
2023
Q1 		$1.46K Sell
15
-15
-50% -$1.55K ﹤0.01% 1410
2022
Q4 		$3.1K Sell
30
-3
-9% -$282 ﹤0.01% 1051
2022
Q3 		$3K Hold
33
– – ﹤0.01% 880
2022
Q2 		$3K Buy
+33
New +$2.63K ﹤0.01% 899
2021
Q4 		$4K Buy
40
+2
+5% +$165 ﹤0.01% 835
2021
Q3 		$3K Buy
+38
New +$3K ﹤0.01% 884

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Bell Investment Advisors's BMRN Position: Q2 2026 in Review

Bell Investment Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 64% in Q2 2026, selling an estimated $5.59K and leaving 57 shares worth $3.26K. The position accounts for ﹤0.01% of the portfolio, ranked #1156.

Bell Investment Advisors first reported a position in BMRN in Q3 2021 and has held it in 19 quarters since. The position peaked at $8.98K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Bell Investment Advisors held 57 shares of BioMarin Pharmaceuticals worth $3.26K as of Q2 2026.
  • Bell Investment Advisors sold 102 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $5.59K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1156 holding.
  • Bell Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • Bell Investment Advisors's BioMarin Pharmaceuticals position peaked at $8.98K in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.